Protagonist Therapeutics and Takeda presented detailed 32-week results from the Phase 3 VERIFY study of rusfertide in patients with polycythemia vera (PV) at the 61st American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session. The study met its primary and all key secondary endpoints, confirming earlier topline results.
The data showed that 76.9% of patients treated with rusfertide plus standard of care achieved a clinical response, defined as the absence of phlebotomy eligibility during Weeks 20-32, compared to 32.9% in the placebo group (p<0.0001). This response was consistent across various patient subgroups.
Rusfertide was generally well tolerated, with the majority of adverse events being low grade and non-serious, and no evidence of increased cancer risk at the time of primary analysis. These comprehensive results strongly support rusfertide's potential as a first-in-class erythrocytosis-specific treatment for PV.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.